Novo Nordisk, Septerna sign $2.2B deal to develop weight-loss pill

May 14, 2025 06:35 AM PDT | By EODHD

Google News:

Novo Nordisk, Septerna sign $2.2B deal to develop weight-loss pill — Image source: Kalkine Media

Recent News

Carnival Corporation (NYSE:CCL) Share Trimmed Tracks NYSE Composite

Celsius Holdings Inc (NASDAQ:CELH) Sees Position Boost by Wealth Firm...

Janney Montgomery Scott Expands Stake in Jabil Inc (NYSE:JBL) Shares S...

ResMed (NYSE:RMD) Shows Growth in ROCE and Business Efficiency NYSE Co...

Pharmaceutical giant Novo Nordisk (NVO) inks a $2.2 billion deal with biotech company Septerna (SEPN) to develop a GLP-1 weight-loss drug in the form of an oral pill. Septerna's stock is skyrocketing by over 60% in Wednesday's pre-market session (at the time of this video's posting). Yahoo Finance senior health reporter Anjalee Khemlani outlines the latest news on this deal and the details of this agreement. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. Video Transcript 00:00 Speaker A Novo Nordisk agreeing to a deal with US biotech firm Cepturna to develop oral pills to treat obesity.

Yahoo Finance senior health reporter Anjalee Khemlani joins us now with more. So, how does this fit into the existing portfolio at Novo? 00:18 Anjalee Khemlani This actually is part of a series of deals that Novo seems to be interested in because pills are seen as the next frontier for the hot obesity market. So this 2.2 billion deal builds on another deal most recently in March that Novo announced that was 1.75 billion. So you can see that price range about similar there for those deals. Cepturna specifically having four candidates that it's looking at and those platforms looking to come to market early stage right now.

So Cepturna is sort of in charge of leading those through the early stage where they figure out what the dosing is, and then Novo would take over after that. That fits into what Novo Nordisk is looking at, which is its own pipeline having some candidates, but questions about whether or not they can come to market quick enough. They do have an application in for a pill version of Wegovy that the FDA is set to look at and decide on by the end of the year. Meanwhile, we know this also lines up with competition with Lilly, which has its own pill that seems to be further along and potentially the first to market. That looking to be in the market by next year.

So really the obesity market heating up in terms of the pill space and this is why Novo is pursuing those deals. Related Videos 01:41 UnitedHealth suspends guidance as CEO steps down. Stock takes hit. Yahoo Finance Video • 23 hours ago 01:00 Fox One, SoftBank delays investment, Zepbound weight loss Yahoo Finance Video • yesterday 09:45 Biocon Executive Chairperson on Insulin Capacity Bloomberg • 2 days ago 04:10 UrbanStems To Ship 4 Million Stems on Mother's Day Bloomberg • 4 days ago View Comments

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.